189 related articles for article (PubMed ID: 11150716)
1. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors.
Kennel SJ; Mirzadeh S; Hurst GB; Foote LJ; Lankford TK; Glowienka KA; Chappell LL; Kelso JR; Davern SM; Safavy A; Brechbiel MW
Nucl Med Biol; 2000 Nov; 27(8):815-25. PubMed ID: 11150716
[TBL] [Abstract][Full Text] [Related]
2. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.
Kumar SR; Deutscher SL
J Nucl Med; 2008 May; 49(5):796-803. PubMed ID: 18413389
[TBL] [Abstract][Full Text] [Related]
3. PEGylation enables the specific tumor accumulation of a peptide identified by phage display.
Mier W; Krämer S; Zitzmann S; Altmann A; Leotta K; Schierbaum U; Schnölzer M; Eisenhut M; Haberkorn U
Org Biomol Chem; 2013 Apr; 11(16):2706-11. PubMed ID: 23474823
[TBL] [Abstract][Full Text] [Related]
4. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
[TBL] [Abstract][Full Text] [Related]
5. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts.
Lee FT; Rigopoulos A; Hall C; Clarke K; Cody SH; Smyth FE; Liu Z; Brechbiel MW; Hanai N; Nice EC; Catimel B; Burgess AW; Welt S; Ritter G; Old LJ; Scott AM
Cancer Res; 2001 Jun; 61(11):4474-82. PubMed ID: 11389078
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
7. Identification of synovium-specific homing peptides by in vivo phage display selection.
Lee L; Buckley C; Blades MC; Panayi G; George AJ; Pitzalis C
Arthritis Rheum; 2002 Aug; 46(8):2109-20. PubMed ID: 12209516
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.
Kobayashi H; Wu C; Yoo TM; Sun BF; Drumm D; Pastan I; Paik CH; Gansow OA; Carrasquillo JA; Brechbiel MW
J Nucl Med; 1998 May; 39(5):829-36. PubMed ID: 9591585
[TBL] [Abstract][Full Text] [Related]
9. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
10. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.
Wilson JJ; Ferrier M; Radchenko V; Maassen JR; Engle JW; Batista ER; Martin RL; Nortier FM; Fassbender ME; John KD; Birnbaum ER
Nucl Med Biol; 2015 May; 42(5):428-438. PubMed ID: 25684650
[TBL] [Abstract][Full Text] [Related]
12. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution of filamentous phage peptide libraries in mice.
Zou J; Dickerson MT; Owen NK; Landon LA; Deutscher SL
Mol Biol Rep; 2004 Jun; 31(2):121-9. PubMed ID: 15293788
[TBL] [Abstract][Full Text] [Related]
14. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells.
Drecoll E; Gaertner FC; Miederer M; Blechert B; Vallon M; Müller JM; Alke A; Seidl C; Bruchertseifer F; Morgenstern A; Senekowitsch-Schmidtke R; Essler M
PLoS One; 2009 May; 4(5):e5715. PubMed ID: 19479088
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.
Milenic DE; Roselli M; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Brechbiel MW; Schlom J
Cancer Biother Radiopharm; 2001 Apr; 16(2):133-46. PubMed ID: 11385960
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
[TBL] [Abstract][Full Text] [Related]
17. Improved in vivo stability and tumor targeting of bismuth-labeled antibody.
Ruegg CL; Anderson-Berg WT; Brechbiel MW; Mirzadeh S; Gansow OA; Strand M
Cancer Res; 1990 Jul; 50(14):4221-6. PubMed ID: 2364380
[TBL] [Abstract][Full Text] [Related]
18. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA).
Camera L; Kinuya S; Garmestani K; Brechbiel MW; Wu C; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
Eur J Nucl Med; 1994 Jul; 21(7):640-6. PubMed ID: 7957350
[TBL] [Abstract][Full Text] [Related]
19. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
20. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.
Shi J; Kim YS; Chakraborty S; Zhou Y; Wang F; Liu S
Amino Acids; 2011 Nov; 41(5):1059-70. PubMed ID: 20052508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
